Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Brandes International ETF (BINV)

Brandes International ETF (BINV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fund Basics

See More
  • Fund Family Brandes Investments
  • Assets Under Management 324,146,400
  • Shares Outstanding, K 8,000
  • 60-Month Beta 0.40
  • Price/Earnings ttm 12.65
  • Annual Dividend & Yield 0.80 (1.97%)
  • Most Recent Dividend 0.127 on 09/29/25
  • Management Fee 0.70%

Price Performance

See More
Period Period Low Period High Performance
1-Month
39.10 +3.63%
on 11/28/25
40.60 -0.20%
on 12/26/25
+1.28 (+3.26%)
since 11/26/25
3-Month
36.93 +9.72%
on 10/22/25
40.60 -0.20%
on 12/26/25
+2.31 (+6.04%)
since 09/26/25
52-Week
28.93 +40.07%
on 04/09/25
40.60 -0.20%
on 12/26/25
+10.24 (+33.80%)
since 12/26/24

Most Recent Stories

More News
Transgene and BioInvent Joint Paper on BT-001 Wins JITC “Best Oncolytic and Local Immunotherapy Paper” Award for 2022

Regulatory News:

BINV : 40.52 (+0.39%)
CASI PHARMACEUTICALS AND BIOINVENT ANNOUNCE DOSING OF FIRST PATIENT IN BI-1206 PHASE 1 CLINICAL TRIAL FOR THE TREATMENT OF RELAPSED/REFRACTORY NON-HODGKIN'S LYMPHOMA IN CHINA

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics...

BINV : 40.52 (+0.39%)
CASI : 0.7895 (+0.96%)
Transgene and BioInvent Announce Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BT-001 in Combination with KEYTRUDA®

Regulatory News:

BINV : 40.52 (+0.39%)
Transgene and BioInvent Announce Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BT-001 in Combination with KEYTRUDA®

Regulatory News:

BINV : 40.52 (+0.39%)
Transgene and BioInvent Announce Positive Progress for BT-001

Regulatory News:

BINV : 40.52 (+0.39%)
Exelixis and BioInvent Establish Exclusive Option and License Agreement to Develop Novel Antibody-Based Immuno-Oncology Therapies

Exelixis, Inc. (Nasdaq: EXEL) and BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV) today announced that the companies have entered into an option and license agreement focused on...

BINV : 40.52 (+0.39%)
EXEL : 46.24 (-0.58%)
Transgene and BioInvent Joint JITC Publication Demonstrates the Potential of BT-001 Oncolytic Virus to Provide Therapeutic Benefit Beyond Current Anti-PD1/ Anti-CTLA-4 Immune Checkpoint Blockade

Regulatory News:

BINV : 40.52 (+0.39%)
BioInvent Moves to NASDAQ Stockholm’s Mid Cap Segment

LUND, SWEDEN / ACCESSWIRE / December 20, 2021 / BioInvent International (STO:BINV) Lund, Sweden - December 20, 2021 - BioInvent International AB ("BioInvent") (NASDAQ Stockholm: BINV), a biotech company...

BINV : 40.52 (+0.39%)
BioInvent announces positive early data from ongoing solid cancer trial of BI-1206 in combination with pembrolizumab

LUND, SE / ACCESSWIRE / December 17, 2021 / BioInvent International (STO:BINV) - Partial response in metastatic uveal melanoma, a difficult-to-treat indication - Markedly improvement of stage IV sarcoma...

BINV : 40.52 (+0.39%)
MRK : 106.78 (+0.31%)
BioInvent’s Latest NHL Data at ASH Show Increased and Sustained Responses to BI-1206 in Relapsed Patients

- Objective response rate (ORR) 67% and disease control rate (DCR) 78% in Follicular lymphoma - Complete responses lasting beyond 18, 24 and 36 months LUND, SWEDEN / ACCESSWIRE / December 11, 2021 / BioInvent...

BINV : 40.52 (+0.39%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

See More Share

Fund Summary

The Brandes International ETF seeks long-term capital appreciation by investing in equity securities of non-U.S. issuers that the Fund's investment team believes are undervalued relative to their financial strength and upside potential.

See More

Top 10 Holdings

Name % Holdings

See More

Key Turning Points

3rd Resistance Point 40.83
2nd Resistance Point 40.71
1st Resistance Point 40.62
Last Price 40.52
1st Support Level 40.41
2nd Support Level 40.29
3rd Support Level 40.20

See More

52-Week High 40.60
Last Price 40.52
Fibonacci 61.8% 36.14
Fibonacci 50% 34.76
Fibonacci 38.2% 33.39
52-Week Low 28.93

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar